HEM Pharma KRX:376270KOSDAQ
HEM파마 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, HEM Pharma reported revenue of ₩4.6bn, up 60.8% year on year, and an operating loss of ₩2.9bn. HEM Pharma (HEM파마) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
HEM Pharma quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.6bn | +60.8% | −₩2.9bn margin −62.5% | ₩1.4bn |
| Q1 2026 | ₩4.9bn | +40.8% | −₩3.8bn margin −77.8% | −₩4.0bn |
| Q4 2025 derived | ₩3.7bn | -41.9% | −₩6.8bn margin −184.1% | −₩14.6bn |
| Q3 2025 | ₩3.0bn | -8.3% | −₩3.6bn margin −120.4% | −₩3.5bn |
| Q2 2025 | ₩2.8bn | -3.1% | −₩2.9bn margin −102.1% | −₩3.3bn |
| Q1 2025 | ₩3.5bn | +35.6% | −₩2.4bn margin −67.4% | −₩2.3bn |
| Q4 2024 derived | ₩6.3bn | +187.0% | −₩2.0bn margin −31.4% | −₩2.0bn |
| Q3 2024 | ₩3.2bn | +300.5% | −₩2.2bn margin −69.1% | −₩2.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
HEM Pharma top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.